Clomiphene Citrate Starting Dose Recommendations
For Women with Ovulatory Dysfunction
Start with 50 mg daily for 5 days, beginning on or about cycle day 5. 1
Initial Dosing Protocol
- 50 mg daily for 5 days is the recommended starting dose for all women with anovulatory infertility 1
- Therapy should begin on approximately the 5th day of the cycle (either after progestin-induced bleeding or spontaneous uterine bleeding) 1
- Coitus should be timed 5-10 days after completing the clomiphene course, when ovulation typically occurs 1
Dose Escalation Strategy
- If no ovulation occurs after the first 50 mg course, increase to 100 mg daily for 5 days in the subsequent cycle 1
- The 100 mg dose can be started as early as 30 days after the previous course, after excluding pregnancy 1
- Doses beyond 100 mg/day for 5 days are not recommended by the FDA 1
- Discontinue clomiphene after 3 ovulatory cycles without pregnancy, or after 3 courses without ovulation 1
- Total treatment should not exceed approximately 6 cycles 1
Special Populations Requiring Lower Initial Doses
- Women with polycystic ovary syndrome (PCOS) may require particularly low doses due to unusual sensitivity to pituitary gonadotropins and increased risk of ovarian hyperstimulation syndrome 1
- The ACOG recommends clomiphene as first-line therapy for anovulatory infertility, with approximately 80% achieving ovulation and 50% of ovulators conceiving 2, 3
Critical Prerequisites Before Starting Treatment
- Adequate endogenous estrogen levels must be present - clomiphene is contraindicated in hypogonadotropic hypogonadism 2, 3, 4, 1
- Exclude pregnancy, ovarian cysts, and abnormal vaginal bleeding before each treatment cycle 1
- Normal liver function is required - clomiphene is contraindicated in liver disease, especially decompensated cirrhosis 2, 3, 4
- Pelvic examination is mandatory before the first and each subsequent course 1
Expected Outcomes and Monitoring
- Most patients who will ovulate do so after the first course of therapy 1
- Once ovulation is established at 50 mg, there is no advantage to increasing the dose in subsequent cycles 1
- Approximately 50% of women who ovulate with clomiphene will conceive after 3 ovulatory cycles 5
Alternative Dosing for Clomiphene-Resistant Cases
- For women who fail standard doses (≥150 mg for 5 days), an extended 10-day course of 100 mg (days 3-12) may induce ovulation in 47% of resistant cases 6
- However, this extended regimen is not FDA-approved and should only be considered after standard therapy fails 6
Key Safety Considerations
- Cancel the cycle if more than 2 dominant follicles >15 mm or more than 5 follicles >10 mm develop to prevent high-order multiple pregnancies 7
- Clomiphene causes significantly thinner endometrium compared to gonadotropins, potentially impairing implantation 2
- Ovarian hyperstimulation syndrome risk increases with multifollicular development 2, 3, 4
For Men with Hypogonadism
Clomiphene citrate is NOT FDA-approved for male hypogonadism and should not be used as primary treatment in men not desiring fertility preservation. 1, 8
Off-Label Use Context
- The FDA label explicitly states: "There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility" 1
- Testicular tumors and gynecomastia have been reported in males using clomiphene, though causality is not established 1
- Despite lack of FDA approval, retrospective data show 88% of men achieve eugonadism with long-term clomiphene use (mean 52 months), with 77% reporting symptom improvement 8
Typical Off-Label Dosing (When Used)
- While no standardized FDA-approved regimen exists, research protocols typically use 25-50 mg daily or every other day for men 8
- Long-term use (>3 years) appears safe with only 8% reporting side effects (mood changes, blurred vision, breast tenderness) 8
Critical Caveat
Clomiphene should not be offered as primary treatment for male hypogonadism outside of fertility preservation contexts, as it lacks FDA approval for this indication 1, 8